Little and large
The human genome project is significant not only for its widely celebrated scientific and medical implications, but as an implicit announcement that the era of 'big science' has well and truly dawned in molecular biology. 'Big science' is a phrase that is most commonly applied to the particle accelerators used by high-energy physicists and the telescopes used by modern astronomers. Until recently, it was rarely associated with biology.
Throughout the brief history of molecular biology and genetics, both disciplines have been pursued mainly in the time-honored manner of the university research laboratory. Broadly speaking, principle investigators lead small and narrowly focused laboratory teams through a series of discrete research projects. The projects are most-often supported by discrete research grants and the outcome, with luck, is published in a peer-reviewed journal. It is accredited to the team and, perhaps, to a small number of outside collaborators, whose names are listed such as to indicate the relative importance of their respective contributions.
So foreign has the concept of 'big science' been to molecular biology, that when one James Watson first proposed the human genome project in the United States a decade or so ago, many biologists had trouble grasping what he had in mind. Soundly rebuffed by the National Institutes of Health (NIH), the project initially found support only from the US Department of Energy (DoE). The DoE knew a bit about genetics, because its researchers at the Los Alamos national laboratory in New Mexico, and elsewhere, had pioneered the early study on the genetic effects of the atomic bomb. It knew even more about big science, because big science was, and remains, how most of the physicists in its laboratories do their work.
The publicly funded human genome project started its life as an uneasy amalgam between 'big' and 'small' science. Dozens of university-based teams were involved in their little parts of the mammoth project. Eventually, prodded by the aggressive sequencing operation established by Celera Genomics at Rockville, Maryland, the public project came to resemble an industrial operation. Sequencing became heavily concentrated at four major centers, whose way of working bore little resemblance to that of a normal university research laboratory.
But it isn't just genomic sequencing that has been witness to the migration towards 'big' biology. Increasingly, biologists are using tools and working with large, interdisciplinary groups of colleagues and technicians, in ways that reshape their professional lives.
Perhaps the most ubiquitous of these emerging tools is the synchrotron light source. The synchrotron was originally developed by the particle physicists as a volume 27 no. 2 february 2001
means of accelerating charged particles around a ring: by serendipity, the bending particles were found to throw off penetrating X-rays. Physicists and material scientists soon found that they could use these X-rays to study crystal structures in unprecedented detail. Only slowly did biologists discover that they could do the same with protein structures. But today, at facilities such as the National Synchrotron Light Source at the DoE's Brookhaven National Laboratory on Long Island, New York, the structural biologists have become the largest single user group.
Another new tool of choice for molecular biologists is the supercomputer, whose development has hitherto been driven primarily by nuclear weapons scientists, cryptographers and weather forecasters. Biologists are now using supercomputers to correlate gene sequence data, for example, and to successfully model protein structures. With an eye to the explosive potential of such activity, IBM says that it is spending tens of millions of dollars to develop what it terms "Blue Gene" (Nature 402, 705-706; 1999), a computer for biologists.
The fast-expanding use of such expensive and sophisticated research tools by biologists is raising a number of interesting operational issues for the community.
The biologists at the synchrotrons, for example, are occasionally perceived as 'drive-through' users who take machine time without contributing anything back to facilities that are made available to them for free. This contrasts with the behavior of the physicists, who work intimately with facility staff over long periods of time to progressively refine the performance of the facility itself.
In the burgeoning field of bioinformatics, meanwhile, an acute skill shortage has quickly developed as teams of geneticists and other biologists struggle to extract maximum benefit from their new computing tools. Even the wealthiest research universities in the United States are poorly positioned to compete with drug companies for rare bioinformatics skills.
Big biology is also leading to a rethink at biomedical research funding agencies and philanthropies. The DoE does most of the heavy lifting in providing major facilities for American scientists, and the National Science Foundation provides the supercomputers that are available to university researchers. As the NIH budget soars -it will exceed $20 billion this year -the agency is being asked to start pulling its weight. Under the directorship of Harold Varmus, the biomedical research agency has started to help the DoE with synchrotron refurbishment to the tune of $20 million a year, and to bolster its tiny supercomputer program: a larger shift of resources surely lies ahead.
A similar dynamic is taking effect at the world's two largest medical research philanthropies, the Howard Hughes Medical Institute (HHMI) and the Wellcome Trust. The Wellcome has agreed to split the $300 million cost of a new synchrotron light source with the British government. Meanwhile Thomas Cech, the new president of the HHMI, declared an early interest in building computing centers for Hughes investigators. The institute has already provided large-scale support for synchrotron instrumentation. Cech can be expected to go further, remolding the traditional HHMI model that confined itself to the generous support of talented principle investigators at their universities.
The implications of the shift toward big biology also extend into scientific publishing, and even to notions of democracy and fairness in the allocation of scientific credit. High-energy physicists publish their work in lengthy papers, with several hundred authors listed in alphabetical order. The experiments have spokespersons, not principle investigators. If a university appointments board wants to know which of the authors really did the work, it has to ask, and take the trouble to understand the answer.
The large and disparate teams involved in the gene sequencing and annotation of various organisms bear more structural resemblance to the particle physicists than to most of their fellow biologists. The question of how the credit for this work should be distributed is just another thorny issue poised by the advent of the new, big biology.
